Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Quantitative score modulation of HSP90 and HSP27 in clear cell renal cell carcinoma.
Massari F, Ciccarese C, Porcaro AB, Ferrero S, Gazzano G, Artibani W, Modena A, Bria E, Sava T, Caliò A, Novara G, Ficarra V, Chilosi M, Martignoni G, Bosari S, Cheng L, Tortora G, Brunelli M. Massari F, et al. Among authors: sava t. Pathology. 2014 Oct;46(6):523-6. doi: 10.1097/PAT.0000000000000150. Pathology. 2014. PMID: 25188333
Reprofiling Metastatic Samples for Chromosome 9p and 14q Aberrations as a Strategy to Overcome Tumor Heterogeneity in Clear-cell Renal Cell Carcinoma.
Massari F, Ciccarese C, Bria E, Porta C, La Russa F, Knuutila S, Artibani W, Porcaro AB, Bimbatti D, Modena A, Sava T, Tortora G, Cheng L, Eccher A, Cima L, Pedron S, Ghimenton C, Martignoni G, Brunelli M. Massari F, et al. Among authors: sava t. Appl Immunohistochem Mol Morphol. 2017 Jan;25(1):39-43. doi: 10.1097/PAI.0000000000000257. Appl Immunohistochem Mol Morphol. 2017. PMID: 26509904
Methods to identify molecular expression of mTOR pathway: a rationale approach to stratify patients affected by clear cell renal cell carcinoma for more likely response to mTOR inhibitors.
Fiorini C, Massari F, Pedron S, Sanavio S, Ciccarese C, Porcaro AB, Artibani W, Bertoldo F, Zampini C, Sava T, Ficial M, Caliò A, Chilosi M, D'Amuri A, Sanguedolce F, Tortora G, Scarpa A, Delahunt B, Porta C, Martignoni G, Brunelli M. Fiorini C, et al. Among authors: sava t. Am J Cancer Res. 2014 Nov 19;4(6):907-15. eCollection 2014. Am J Cancer Res. 2014. PMID: 25520878 Free PMC article.
Predictive role of changes in the tumor burden and International Metastatic Renal Cell Carcinoma Database Consortium class during active surveillance for metastatic renal cell carcinoma.
Bimbatti D, Ciccarese C, Fantinel E, Sava T, Massari F, Bisogno I, Romano M, Porcaro A, Brunelli M, Martignoni G, Mazzarotto R, Artibani W, Tortora G, Iacovelli R. Bimbatti D, et al. Among authors: sava t. Urol Oncol. 2018 Dec;36(12):526.e13-526.e18. doi: 10.1016/j.urolonc.2018.08.018. Epub 2018 Oct 6. Urol Oncol. 2018. PMID: 30301699
Cathepsin K expression in castration-resistant prostate carcinoma: a therapeutical target for patients at risk for bone metastases.
Munari E, Cima L, Massari F, Bertoldo F, Porcaro AB, Caliò A, Riva G, Ciocchetta E, Ciccarese C, Modena A, Iacovelli R, Sava T, Eccher A, Ghimenton C, Tortora G, Artibani W, Novella G, Bogina G, Zamboni G, Sanguedolce F, D'Amuri A, Martignoni G, Brunelli M. Munari E, et al. Among authors: sava t. Int J Biol Markers. 2017 May 4;32(2):e243-e247. doi: 10.5301/jbm.5000246. Int J Biol Markers. 2017. PMID: 28085175 Free article.
Is It Possible to Improve Prognostic Classification in Patients Affected by Metastatic Renal Cell Carcinoma With an Intermediate or Poor Prognosis?
Iacovelli R, De Giorgi U, Galli L, Zucali P, Nolè F, Sabbatini R, Fraccon AP, Basso U, Mosca A, Atzori F, Santini D, Facchini G, Fornarini G, Pasini F, Masini C, Massari F, Buti S, Sava T, Sacco C, Ricotta R, Sperduti I, Tortora G, Porta C. Iacovelli R, et al. Among authors: sava t. Clin Genitourin Cancer. 2018 Oct;16(5):355-359.e1. doi: 10.1016/j.clgc.2018.04.007. Epub 2018 May 7. Clin Genitourin Cancer. 2018. PMID: 29803346
Magnitude of PD-1, PD-L1 and T Lymphocyte Expression on Tissue from Castration-Resistant Prostate Adenocarcinoma: An Exploratory Analysis.
Massari F, Ciccarese C, Caliò A, Munari E, Cima L, Porcaro AB, Novella G, Artibani W, Sava T, Eccher A, Ghimenton C, Bertoldo F, Scarpa A, Sperandio N, Porta C, Bronte V, Chilosi M, Bogina G, Zamboni G, Tortora G, Samaratunga H, Martignoni G, Brunelli M. Massari F, et al. Among authors: sava t. Target Oncol. 2016 Jun;11(3):345-51. doi: 10.1007/s11523-015-0396-3. Target Oncol. 2016. PMID: 26566945
Next-generation repeat-free FISH probes for DNA amplification in glioblastoma in vivo: Improving patient selection to MDM2-targeted inhibitors.
Brunelli M, Eccher A, Cima L, Trippini T, Pedron S, Chilosi M, Barbareschi M, Scarpa A, Pinna G, Cabrini G, Pilotto S, Carbognin L, Bria E, Tortora G, Fioravanzo A, Schiavo N, Meglio M, Sava T, Belli L, Martignoni G, Ghimenton C. Brunelli M, et al. Among authors: sava t. Cancer Genet. 2017 Jan;210:28-33. doi: 10.1016/j.cancergen.2016.11.004. Epub 2016 Dec 1. Cancer Genet. 2017. PMID: 28212808
79 results